About this reading room

What this site is

Sermorelin Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin acetate — the 29-amino-acid GHRH(1-29) peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The research summaries on this site are organized around a small, deliberately constrained set of primary sources: the original pediatric and adult GHRH(1-29) controlled trials, the historic FDA-approved prescribing information, the 2013 Federal Register determination governing post-discontinuation compounding, and recent peer-reviewed reviews of the GHRH-R receptor and the somatopause clinical landscape. Every quantitative claim on the site cites one of those sources. Where a finding is qualitative or contested, the text says so.

How to read the modifier in the domain name

The 'meds' in the domain is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services. We are not a pharmacy. We do not dispense medication. We do not write prescriptions. The framing simply names the editorial lane: this is the place to read about sermorelin as a medication — its FDA-approval history under NDA 020443, its 2008 commercial discontinuation, its current 503A compounding status, and what the controlled trials in pediatric GHD and adult somatopause have shown.

The distinction matters because sermorelin's regulatory history is unusual. It is one of very few research peptides with a documented FDA approval, a documented withdrawal, and a documented Federal Register finding (78 FR 14114) that the withdrawal was not for safety or efficacy reasons. The medication-history lens is the right one for reading that record — but a medication-history reading room is not a pharmacy, and we want that distinction clear.

Editorial standards

Sources are restricted to peer-reviewed primary literature, peer-reviewed reviews, FDA documents, and Federal Register notices. We cite PubMed, PubMed Central, the publishing journal, the FDA, and the Federal Register directly — never aggregators, never vendor product pages, never marketing materials.

We do not recommend doses. We document the doses that appear in the historic FDA-approved label and in published research trials, and we identify each as such. We do not interpret findings beyond what the source authors themselves report. Where the literature is sparse — for example, on sublingual sermorelin bioavailability — we say so plainly rather than fill the gap with speculation.

We use generic compound names throughout (sermorelin, GHRH(1-29), tesamorelin, ipamorelin, CJC-1295) and avoid registered drug brand names. We do not link to other portfolio sites and we do not link out to vendors, pharmacies, or marketing pages of any kind.

What this site does not do

We do not sell sermorelin or any other product. We do not prescribe. We do not dispense. We do not offer telehealth, consultations, or treatment plans. We do not refer to specific compounding pharmacies, specific clinicians, or specific patient services. We do not maintain a patient roster or a customer database.

The site exists to make the published research on a specific compound easier to read — for human readers and for machine readers. The editorial standards are simple: every quantitative claim cites the primary source it comes from; where the literature is sparse or contested, the text says so plainly.